--- title: "Multiple System Atrophy: Clear 2026 Trial Landscape" description: "Multiple System Atrophy trials in 2026 go beyond the Mayo Clinic study. What else is registered, which cell sources are used, and each current status." url: "https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/" --- # The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied #### Table of Contents - [Oscar Tellez](https://savemyfat.com/author/oscartellez/) - [August 20, 2026](https://savemyfat.com/2026/08/20/) - 10:00 am The multiple system atrophy trial landscape beyond mayo clinic: what else is being studied 2 Families researching multiple system atrophy clinical trials 2026 usually find one study and assume the field is in motion. The verified record is smaller and quieter. This guide reads the Mayo Clinic registry page as written, lists the four other registered cell therapy studies in MSA, and explains why they cannot be combined into one conclusion. **TLDR:** Five registered cell therapy studies in multiple system atrophy appear in the verified record, and every one is small. The Mayo Clinic Phase 2 study, NCT05167721, is Active, not recruiting, with 71 participants enrolled and no results posted. The other four enrolled 9, 10, 27, and 30 participants across three countries, using cell sources that differ from each other. None is FDA approved, none is open to enrollment, and none establishes benefit. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit in any of them. **Important Disclaimer:** Save My Fat is a tissue preservation connector and does not provide FDA-approved treatments or cures. Multiple system atrophy is a serious, progressive neurologic disease, and nothing below should be read as an available option or as evidence that any cell product changes its course. Save My Fat does not run trials, screen participants, or guarantee eligibility, access, or clinical benefit. Adipose tissue and adipose-derived cells are investigational and are not FDA approved for multiple system atrophy. This article is provided for educational purposes only, and readers should consult their own licensed healthcare professionals, including a treating neurologist, before drawing conclusions from any registry page. --- MSA moves fast and takes a great deal from a family in a short time. That pressure changes how people read a registry page. A respected institution’s name starts to look like an answer rather than what it is, a record of an experiment in progress. The verified record holds five registered cell therapy studies in MSA, across three countries and four sponsors, with enrollments in the single and double digits. Two have ended. Three are ongoing but closed to new participants. Nothing here is approved, nothing has reported a result establishing benefit, and every question belongs with a neurologist who knows the patient. ## Read the Mayo Clinic Record Exactly as It Is Written The most discussed study in this field is [NCT05167721](https://clinicaltrials.gov/study/NCT05167721), sponsored by Mayo Clinic at a single site in Rochester, Minnesota. Its registered title is “Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy.” It is a Phase 2 study of adipose-derived autologous mesenchymal stem cells, delivered intrathecally, against placebo. Five fields carry the weight. Status: Active, not recruiting, last verified June 2026, last update posted June 12, 2026. Enrollment: 71 actual. Start date: December 15, 2021, actual. Primary completion and study completion: December 2026, estimated. Results posted: none. Together those fields say something specific. The study is closed to new participants, it has not reported an outcome, and no conclusion about benefit has been established. The record notes funding from the FDA Office of Orphan Products Development and three Mayo Clinic sources. Funding supports research, not agency endorsement, and the intervention remains investigational and not FDA approved. Anyone weighing what this record means should take it to a neurologist. Our [Mayo MSA trial](/mayo-multiple-system-atrophy-trial-nct05167721/) explainer walks the design field by field. --- ## Multiple System Atrophy Clinical Trials 2026: What the Registry Shows Beyond that study, the verified record contains four more registered cell therapy studies in MSA, from four sponsors in three countries. They share no cell source and no single phase. The table states what each record says and nothing beyond it. Registry ID Sponsor Phase Status Cell source Enrollment NCT05167721 Mayo Clinic Phase 2 Active, not recruiting Autologous adipose-derived MSC, intrathecal 71 actual NCT02315027 Mayo Clinic Phase 1/2 Active, not recruiting Autologous MSC, tissue source not stated 30 actual NCT03265444 Corestemchemon Phase 1 Completed Autologous bone marrow derived MSC 9 actual NCT05698017 Cytora Ltd. Phase 1 Active, not recruiting Allogeneic oral mucosa derived stromal cells 10 actual NCT00911365 Yonsei University Phase 2 Completed Autologous MSC, tissue source not stated 27 actual Two are Completed and three are Active, not recruiting. Not one is open to enrollment, none is FDA approved, and no row reports an outcome that establishes benefit in MSA. --- ## MSA Stem Cell Research Beyond Mayo Clinic, Study by Study The second Mayo study, NCT02315027, is registered as “Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA), Effect of Dose and Natural History.” It is Phase 1/2, Active not recruiting, last verified April 2026, with 30 participants in the United States. Its record states no tissue source, so calling it an adipose study would go past the evidence. Corestemchemon ran NCT03265444 in South Korea, a Phase 1 safety and tolerability study of autologous bone marrow derived mesenchymal stem cells, identified as CS10BR05, with 9 participants, now Completed. Cytora Ltd. sponsors NCT05698017 in Israel, a Phase 1 study of hOMSC300, an allogeneic product from oral mucosa stromal cells, with 10 participants, Active and not recruiting, last verified January 2025. Yonsei University ran NCT00911365 in South Korea, Phase 2, 27 participants, Completed, tissue source not stated. All of it is investigational, none is FDA approved, and none establishes a result a patient can act on. A neurologist should read these records for a specific case. --- ## Why These Five Records Cannot Be Added Together The instinct is to total a list like that, and the studies do not support it. The largest enrolled 71 participants and the smallest enrolled 9. Work at that size can describe feasibility and safety signals. It is not designed to show that a product changes a disease. The cell sources also differ more than the shared label suggests. One used adipose-derived cells, one bone marrow, one allogeneic oral mucosa derived stromal cells, and two records state no source. The [ISCT minimal criteria](https://pubmed.ncbi.nlm.nih.gov/16923606/) from Dominici and colleagues, published in Cytotherapy in 2006, require plastic adherence, expression of CD105, CD73 and CD90, absence of markers including CD45, CD34 and HLA-DR, and trilineage differentiation in vitro. Those are minimum identity criteria. Meeting them does not make cells from different tissues interchangeable, and says nothing about clinical effect. ### Completed Does Not Mean It Worked, and Neither Does Active The registry’s own [status glossary](https://clinicaltrials.gov/study-basics/glossary) defines Active, not recruiting as “The study is ongoing, and participants are receiving an intervention or being examined, but potential participants are not currently being recruited or enrolled.” Completed means “The study has ended normally, and participants are no longer being examined or treated (that is, the last participant’s last visit has occurred).” Both describe conduct. Neither reports a result. Under [42 CFR Part 11](https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-11), applicable trials must generally submit results within one year after the primary completion date, and compliance is uneven. Where a page is silent, the next place to look is a peer-reviewed publication, read with a clinician rather than alone. --- ## Nothing in This Field Is Near FDA Approval Approval status lives on FDA’s list of [approved cellular and gene therapy products](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products), not on a clinic website. The only FDA-approved mesenchymal stromal cell therapy is RYONCIL, approved December 18, 2024 for steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older. It is an allogeneic bone marrow derived product, and that indication has not changed. There is no FDA-approved cell therapy for multiple system atrophy. FDA’s [consumer alert on regenerative medicine products](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes) names arthritis, back pain, Parkinson’s, ALS, Alzheimer’s, cardiovascular and lung disease, autism, blindness and COVID-19 among conditions these products are not approved for, and states that blood-forming stem cells from cord blood are the only approved stem cell products. A clinic selling cells for MSA is selling something unapproved. --- ## What This Means for a Family Searching Right Now None of the five studies here is recruiting, in the United States or anywhere else. The verified snapshot of [recruiting adipose cell studies](https://clinicaltrials.gov/search?term=adipose%20derived%20mesenchymal%20stem%20cells&aggFilters=status:rec) as of July 27, 2026 covers knee osteoarthritis, stress urinary incontinence, burn scar remodeling, xerostomia in Sjogren syndrome, recurrent glioblastoma, chronic traumatic brain injury, Crohn disease, acute kidney injury, and Alzheimer disease. Multiple system atrophy is not among them, and a wider view sits in our roundup of [adipose MSC trials](/active-clinical-trials-in-adipose-derived-mscs-2026/). Eligibility is set by each protocol and judged by the study team, never by a patient, a marketer, or a bank. Banking adipose tissue does not create eligibility, open a study, or shorten screening. If a new MSA study opens later, [vetting clinical trials](/how-to-find-legitimate-clinical-trials-in-2026/) starts with the registry record and ends with the neurologist. --- ## Frequently Asked Questions ### What other institutions besides Mayo Clinic are studying MSA and stem cells? The verified record names three. Corestemchemon in South Korea ran NCT03265444, Phase 1, autologous bone marrow derived MSCs, 9 participants. Cytora Ltd. in Israel sponsors NCT05698017, allogeneic oral mucosa derived stromal cells, 10 participants. Yonsei University ran NCT00911365 in South Korea, Phase 2, 27 participants. All remain investigational and none is FDA approved. ### How does the broader MSA trial landscape compare to the Mayo Clinic study? Mayo’s NCT05167721 is the largest of the five at 71 participants, and the only one recorded as using adipose-derived cells. The others enrolled 9, 10, 27, and 30. Mayo also runs the second United States study, NCT02315027, at Phase 1/2. Small numbers limit what any of them can conclude. ### Is any MSA cell therapy close to FDA approval? No. FDA’s list of approved cellular and gene therapy products contains no cell therapy for multiple system atrophy. The only approved mesenchymal stromal cell therapy is RYONCIL, cleared December 18, 2024 for steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older. Everything here is investigational, with results not established. ### What should MSA patients know about clinical trial eligibility? Eligibility comes from the protocol, which sets diagnosis criteria, disease stage, prior treatments, and site requirements. The study team decides, and a closed study cannot make exceptions. Three of these five are Active, not recruiting, meaning ongoing but not enrolling. Bring any record you find to your neurologist before contacting a site. ### Are these trials using adipose-derived cells or other cell sources? The sources differ. NCT05167721 uses autologous adipose-derived MSCs delivered intrathecally. NCT03265444 used autologous bone marrow derived MSCs. NCT05698017 uses allogeneic oral mucosa derived stromal cells. NCT02315027 and NCT00911365 state no tissue source, so neither should be described as an adipose study. Those differences make pooled conclusions unsupportable. ### Does banking adipose tissue give someone access to an MSA study? No. Save My Fat is a connector to a tissue bank and does not run trials, sponsor research, screen participants, or influence enrollment. Banked tissue does not guarantee eligibility, access, or clinical benefit, and no study named here is enrolling. Decisions about research participation belong with the neurologist and the study team. --- ## Key Takeaways The MSA cell therapy landscape in 2026 is five registered studies, not a movement. Mayo Clinic’s NCT05167721 is Phase 2, Active and not recruiting as of its June 2026 verification, with 71 participants, a December 15, 2021 start, completion estimated for December 2026, and no results posted. The other four come from Mayo, Corestemchemon, Cytora, and Yonsei University, enrolling 30, 9, 10, and 27 participants across the United States, South Korea, and Israel. Two are Completed, three are Active and not recruiting, and none is open today. Their cell sources include adipose, bone marrow, and allogeneic oral mucosa, with two records stating no source, which is why these studies cannot be pooled. Nothing here is FDA approved for multiple system atrophy, results are not established, and what any of it means for a specific person belongs with a neurologist. Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time. Families comparing preservation options can review [current pricing](https://savemyfat.com/pricing/), and process questions go to our [contact page](/contact-us/). --- *Save My Fat partners with L2 Bio for laboratory processing and storage.* *This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about banking, treatment, or research participation.* **About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice. **Related guide:** [adipose stem cell trials](https://savemyfat.com/adipose-stem-cell-clinical-trials/). [PrevPreviousRyoncil in 2026: What Changed Since the First FDA-Approved MSC Therapy](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/) [NextWhat Happens If a Clinical Trial for Adipose-Derived Cells Is Terminated EarlyNext](https://savemyfat.com/terminated-clinical-trial-what-it-means/) Providers ### [Urologist Guide to Adipose Banking and the Erectile Dysfunction Research Landscape](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/) [Read More »](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/) Oscar Tellez 08/23/2026 10:00 AM Providers ### [Dermatologist Guide to Adipose Banking: What the Research Landscape Looks Like in 2026](https://savemyfat.com/dermatologist-adipose-banking-guide/) [Read More »](https://savemyfat.com/dermatologist-adipose-banking-guide/) Oscar Tellez 08/22/2026 10:00 AM Clinical Trials ### [What Happens If a Clinical Trial for Adipose-Derived Cells Is Terminated Early](https://savemyfat.com/terminated-clinical-trial-what-it-means/) [Read More »](https://savemyfat.com/terminated-clinical-trial-what-it-means/) Oscar Tellez 08/21/2026 10:00 AM [![Multiple System Atrophy shown on a translucent blue anatomical model of a brain](https://savemyfat.com/wp-content/uploads/2026/07/August-20-768x768.png)](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/) Clinical Trials ### [The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/) [Read More »](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/) Oscar Tellez 08/20/2026 10:00 AM [![Ryoncil approval timeline shown as an hourglass beside a single glass vial](https://savemyfat.com/wp-content/uploads/2026/07/August-19-768x768.png)](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/) Regulation ### [Ryoncil in 2026: What Changed Since the First FDA-Approved MSC Therapy](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/) [Read More »](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/) Oscar Tellez 08/19/2026 10:00 AM Clinical Trials ### [NCT06002841 Explained: What This Registered Clinical Trial Is Studying](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/) [Read More »](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/) Oscar Tellez 08/18/2026 10:00 AM ```json [{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"#article","headline":"Multiple System Atrophy: Clear 2026 Trial Landscape","name":"Multiple System Atrophy: Clear 2026 Trial Landscape","datePublished":"2026-08-20T10:00:00-04:00","dateModified":"2026-08-20T10:00:00-04:00","description":"Multiple System Atrophy trials in 2026 go beyond the Mayo Clinic study. What else is registered, which cell sources are used, and each current status.","inLanguage":"en-US","image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-20.png","isPartOf":{"@id":"#webpage"},"author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"articleSection":"Adipose, Clinical Trials, Stem Cells"},{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","sameAs":["https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.linkedin.com\/company\/save-my-fat","https:\/\/www.instagram.com\/savemyfat\/","https:\/\/search.sunbiz.org\/Inquiry\/CorporationSearch\/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=SAVEMYFAT%20L260000005000&aggregateId=flal-l26000000500-32d6bf22-6788-4c6f-a062-b944408d7cda&searchTerm=SAVE%20MY%20LLC&listNameOrder=SAVEMY%20L250004108200"],"logo":{"@type":"ImageObject","@id":"https:\/\/savemyfat.com\/#logo","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2025\/12\/Blk-Txt-Blk-BG-SMF.svg","contentUrl":"https:\/\/savemyfat.com\/wp-content\/uploads\/2025\/12\/Blk-Txt-Blk-BG-SMF.svg","caption":"Save My Fat","inLanguage":"en-US","width":"500","height":"500"}},{"@type":"WebSite","@id":"https:\/\/savemyfat.com\/#website","url":"https:\/\/savemyfat.com","name":"Save My Fat","alternateName":"https:\/\/savemyfat.com","publisher":{"@id":"https:\/\/savemyfat.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-20.png","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-20.png","width":"1250","height":"1250","caption":"Multiple System Atrophy shown on a translucent blue anatomical model of a brain","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/clinical-trials\/","name":"Clinical Trials"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/","name":"The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied"}}]},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/#webpage","url":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/","name":"Multiple System Atrophy: Clear 2026 Trial Landscape","datePublished":"2026-08-20T10:00:00-04:00","dateModified":"2026-08-20T10:00:00-04:00","isPartOf":{"@id":"https:\/\/savemyfat.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/07\/August-20.png"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/#breadcrumb"},"mainEntity":[{"@type":"Question","name":"What is adipose tissue banking?","acceptedAnswer":{"@type":"Answer","text":"Adipose tissue banking is the process of collecting, processing, and cryopreserving your own body fat for potential future use in FDA-regulated clinical research, Expanded Access programs, or approved therapies. It is a preservation service, not a treatment."}},{"@type":"Question","name":"Is adipose tissue banking FDA-approved?","acceptedAnswer":{"@type":"Answer","text":"Tissue banking as a preservation service is not a product requiring FDA approval. However, any future medical use of stored tissue must comply with FDA regulations at that time. Products derived from adipose tissue that undergo more than minimal manipulation typically require IND applications and a Biologics License Application before legal marketing."}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of SaveMyFat, a national adipose tissue banking company that helps individuals preserve their own fat-derived stem cells for potential future use in FDA-regulated research pathways.","url":"https:\/\/savemyfat.com\/oscar-tellez","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Stem Cell Cryopreservation","Regenerative Medicine","Fat-Derived Stem Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","headline":"The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied","url":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/","datePublished":"2026-08-20T10:00:00-04:00","dateModified":"2026-07-28T19:27:45-04:00","description":"Five registered cell therapy studies in multiple system atrophy appear in the verified record, and every one is small. The Mayo Clinic Phase 2 study, NCT05167721, is Active, not recruiting, with 71 participants enrolled and no results posted. The other four enrolled 9, 10, 27, and 30 participants across three countries, using cell sources that differ from each other. None is FDA approved, none is open to enrollment, and none establishes benefit. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit in any of them.","abstract":"Five registered cell therapy studies in multiple system atrophy appear in the verified record, and every one is small. The Mayo Clinic Phase 2 study, NCT05167721, is Active, not recruiting, with 71 participants enrolled and no results posted. The other four enrolled 9, 10, 27, and 30 participants across three countries, using cell sources that differ from each other. None is FDA approved, none is open to enrollment, and none establishes benefit. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit in any of them.","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"speakable":{"@type":"SpeakableSpecification","cssSelector":["#tldr-summary"],"xpath":["\/\/*[@id=\"tldr-summary\"]"]}}]},{"@context":"https:\/\/schema.org","@type":"WebPage","@id":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/#webpage","url":"https:\/\/savemyfat.com\/multiple-system-atrophy-clinical-trials-2026\/","name":"Multiple System Atrophy Trials Beyond Mayo Clinic","speakable":{"@type":"SpeakableSpecification","cssSelector":[".smf-speakable"]}}] ```